Tovetumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | PDGFRA |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6400H9906N1726O2002S54 |
| Molar mass | 144792.97 g·mol−1 |
Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer.[1] It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer.[2] Development was discontinued in 2013.[3][4]
This drug was developed by MedImmune, LLC.[citation needed]
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
- ^ Liang M, Wang B, Schneider A, Vainshtein I, Roskos L (November 2020). "A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy". The AAPS Journal. 23 (1): 4. doi:10.1208/s12248-020-00523-3. PMID 33210183. S2CID 227067803.
- ^ "Tovetumab". AdisInsight. Springer Nature Switzerland AG.
- ^ Williams R (January 2015). "Discontinued in 2013: oncology drugs". Expert Opinion on Investigational Drugs. 24 (1): 95–110. doi:10.1517/13543784.2015.971154. PMID 25315907. S2CID 23390614.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |